CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENTShare Purchase Agreement • February 5th, 2021 • Meridian Bioscience Inc • In vitro & in vivo diagnostic substances • Quebec
This AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT dated as of December 21, 2020, is entered into between APRÈS-DEMAIN DIAGNOSTICS INC. (formerly known as Genepoc Inc.), a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation incorporated under the laws of British Columbia (“Buyer”), APRÈS-DEMAIN SA (formerly known as APRÈS-DEMAIN HOLDING SA), in its capacity of Shareholders’ Representative, and MERIDIAN BIOSCIENCE, INC.
AMENDMENT TO SHARE PURCHASE AGREEMENTShare Purchase Agreement • February 5th, 2021 • Meridian Bioscience Inc • In vitro & in vivo diagnostic substances • Quebec
This AMENDMENT TO SHARE PURCHASE AGREEMENT (the “Amendment”), dated as of June 3, 2019, is entered into between GENEPOC INC., a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation incorporated under the laws of British Columbia (“Buyer”), THE SHAREHOLDERS OF SELLER (the “Shareholders”), APRÈS-DEMAIN HOLDING SA, in its capacity of Shareholders’ Representative, and MERIDIAN BIOSCIENCE, INC.
